Solid Tumors clinical trials in Arizona
138 active Solid Tumors trials with a site in Arizona. Describe your situation to see which ones look like a fit.
- Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
- Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
- A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
- A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
- Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
- Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
- FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
- SW-682 in Advanced Solid Tumors
- First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
- Pan Tumor Rollover Study
- A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
- A Study of BG-C477 in Participants With Advanced Solid Tumors
- ORB-021 In Patients With Advanced Solid Tumors
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
- Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
- First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
- A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
- A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
- SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
- Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
- A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
- Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Dabrafenib and/or Trametinib Rollover Study
- Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.